Caxton Associates (New York)’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Caxton Associates (New York)’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-83,993	Closed	-$491K	–	680
2022 Q4	$491K	Sell	83,993 -40,122	-32%	-$211K	0.03%	242
2022 Q3	$832K	Buy	+124,115	New	+$752K	0.11%	150

Caxton Associates (New York)'s CNCE Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 83,993 shares — an estimated $491K sold.

Caxton Associates (New York) first reported a position in CNCE in Q3 2022 and held it in 2 quarters. The position peaked at $832K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Caxton Associates (New York) reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Caxton Associates (New York) sold 83,993 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $491K.
Caxton Associates (New York) first reported a position in Concert Pharmaceuticals, Inc. in Q3 2022 and held it in 2 quarters.
Caxton Associates (New York)'s Concert Pharmaceuticals, Inc. position peaked at $832K in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.